Lisa Swanson, MD: New Treatments for Pediatric Atopic Dermatitis

Video

A pediatric dermatologist discusses dupilumab for pediatric atopic dermatitis in addition to promising new therapies.

The recent FDA approval of dupilumab (Dupixent) for children aged 6-11 years has been an important turning point in the treatment narrative of atopic dermatitis. And, as any dermatologist would hope, promising therapies are just visible on the horizon.

In this month’s episode of Derm Discussions, “Unlocking the Pediatric Dermatology Toolbox,” pediatric dermatologist Lisa Swanson, MD, of ADA West Dermatology, discussed the therapeutic benefit of dupilumab for her pediatric patients.

She lauded the biologic agent’s efficacy and safety within this population.

“I tell patients and their families, ‘this is a life-changer for [you],” she said. “It makes me feel better to be able to help these kids in this way.”

A side effect Swanson noted was conjunctivitis; however, she explained her 2-3 cases were mild and easily resolved with a referral to an ophthalmologist.

She also discussed new therapies and formulations that are emerging down the pipeline. For example, she noted topical tapinarof, topical JAK inhibitors, oral JAK inhibitors, and IL-13 blockers.

According to her, the immediate future looks particularly promising for these particular patients.

“I think the past 10-15 years have been the age of psoriasis, and the next 10-15 are going to be the age of atopic dermatitis,” Swanson stressed.

Listen to the full podcast episode below:

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
© 2024 MJH Life Sciences

All rights reserved.